This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Atrial Fibrillation Embolism Stroke 
HeartRhythm
MARCH 14, 2024
Artificial intelligence (AI)-enabled sinus rhythm (SR) electrocardiogram (ECG) interpretation can aid in identifying undiagnosed paroxysmal atrial fibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).
Frontiers in Cardiovascular Medicine
MARCH 3, 2024
Background Covert atrial fibrillation (AF) is a predominant aetiology of embolic stroke of undetermined source (ESUS). Evidence suggested that AF is more frequently detected by implantable loop recorder (ILR) than by conventional monitoring.
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2024
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism.
The New England Journal of Medicine
JANUARY 1, 2025
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.
ECG Cases
SEPTEMBER 12, 2023
The post ECG Cases 45 ECG in Weakness and Neurological Symptoms appeared first on Emergency Medicine Cases.
125 
HeartRhythm
APRIL 30, 2024
Cancer patients have a higher risk of atrial fibrillation (AF) than general population, however, the link between cancer and AF is not fully understood. The association between AF detected by implanted cardiac implantable electronic devices (CIEDs) and the incidence of embolic stroke has been reported.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) has been known as a main cause of embolic stroke. Well-chosen candidate to be anticoagulated should be critical for secondary prevention in patients with embolic stroke with undetermined source (ESUS).
Journal of the American Heart Association
FEBRUARY 14, 2025
BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), data on patients with AF and valvular heart disease remain scarce. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety.
Circulation
JANUARY 24, 2024
The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). interquartile range, 25.2–32.2)
Open Heart
SEPTEMBER 18, 2024
The ‘1–3–6–12 days rule’, based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013. Trial registration number NCT02306824.
HeartRhythm
APRIL 30, 2024
Polygenic risk score (PRS) might be useful in predicting atrial fibrillation (AF)-related stroke/systemic embolsim (SSE) before diagnosis of clinical AF.
HeartRhythm
APRIL 24, 2024
Abnormal conduction, structure and function of the atrial myocardium predispose to atrial fibrillation (AF) and stroke. Usefulness of electrocardiographic (ECG) indices in predicting stroke or systemic embolism (SSE) in patients undergoing cardioversion for AF remains unknown, especially in those at low estimated risk.
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024. Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrial fibrillation (AF).
HeartRhythm
APRIL 30, 2024
AF detection rates with implantable cardiac monitoring (ICM) following cryptogenic stroke are >12% at 12 months. Similar results have been reported in some non-cryptogenic stroke cohorts. Real-world data has also shown a much lower rate of AF detection.
40 
The New England Journal of Medicine
NOVEMBER 11, 2023
In a randomized trial involving patients with subclinical (typically asymptomatic) atrial fibrillation, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.
Medical Xpress - Cardiology
SEPTEMBER 3, 2024
Mass screening for atrial fibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).
Stroke Journal
DECEMBER 21, 2023
Stroke, Volume 55, Issue 1 , Page 214-225, January 1, 2024. Nonvalvular atrial fibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism.
HeartRhythm
APRIL 30, 2024
Clinical, imaging, and genetic markers in combinations might be useful for risk assessment of atrial fibrillation (AF) and related stroke/systemic embolsim (SSE).
DAIC
FEBRUARY 27, 2024
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrial fibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP23-ATP23, February 1, 2025. Background:Stroke is the second leading cause of death worldwide, with atrial fibrillation being a significant risk factor that substantially increases the likelihood of stroke. The primary safety outcome was major bleeding. to 0.87, p = 0.005).
Frontiers in Cardiovascular Medicine
DECEMBER 3, 2024
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrial fibrillation. ResultsA total of 12 studies included 73,824 patients with atrial fibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
Circulation
NOVEMBER 11, 2024
Patients with a history of prior hemorrhagic stroke were excluded from this analysis. Circulation, Volume 150, Issue Suppl_1 , Page A4141940-A4141940, November 12, 2024.
American College of Cardiology
NOVEMBER 17, 2024
Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.
58 Journal of the American Heart Association
JANUARY 31, 2024
BackgroundThere are limited data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation with significant tricuspid regurgitation (TR), which can lead to hepatic dysfunction and intestinal malabsorption. The median follow‐up duration was 2.4 1.06];P=0.11).
American College of Cardiology
JUNE 12, 2024
The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrial fibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm (..)
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundAlthough older patients with atrial fibrillation are at heightened risk of thromboembolic and bleeding events, their optimal treatment choice remains uncertain.Methods and ResultsThis meta‐analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. prospero/.
Open Heart
MARCH 1, 2024
Background Amiodarone is an established treatment for atrial fibrillation (AF) but might interfere with the metabolism of apixaban or warfarin. Exploratory outcomes included ischaemic stroke/systemic embolism and all-cause/cardiovascular (CV) mortality. Rates of major bleeding were similar in the apixaban (4.3/100
HeartRhythm
APRIL 30, 2024
Cryoablation for atrial fibrillation is a widely used technique for pulmonary vein isolation. Known complications associated with cryoablation include tamponade, phrenic nerve injury, stroke, pulmonary embolism, pulmonary vein stenosis, and atrioesophageal fistulas.
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWP171-AWP171, February 1, 2025. Renal dysfunction increases risk of atrial fibrillation, ischemic stroke and systemic bleeding. Subjects with other indication for anticoagulation such as venous thromboembolism, pulmonary embolism, and prosthetic valve were excluded.
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page A145-A145, February 1, 2025. Background:Patients with atrial fibrillation (AF) and previous stroke or transient ischemic attack (TIA) are at high risk of recurrent stroke. respectively; OR = 0.88; 95% CI [0.77, 1.01]; I2= 59%; p = 0.066), disabling or fatal stroke (2.4%
Journal of the American Heart Association
FEBRUARY 14, 2024
BackgroundThe ABC‐stroke score is a risk scheme for prediction of stroke or systemic embolism (SE) in atrial fibrillation (AF). Having an annual ABC‐stroke risk >1% was associated with stroke/SE, stroke/SE/cardiovascular death, and all‐cause death (hazard ratio, 1.82 [95% CI, 1.44–2.21],
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP13-ATP13, February 1, 2025. Background:Atrial fibrillation (AF) patients carry a high risk of stroke, and treatment related bleeding complications. 0.91), P<0.01), stroke by 19% (OR, 0.81(95%CI: 0.97), P=0.02), and hemorrhagic stroke by 57% (OR, 0.43(95%CI:
Open Heart
JANUARY 29, 2024
Aim To assess outcomes after cardiac surgery with biological valve replacement, valve repair or transcatheter aortic valve implantation (TAVI) in patients with atrial fibrillation (AF) in accordance with oral anticoagulant (OAC) treatment. Methods All patients in Sweden undergoing valvular intervention with AF were included.
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP199-AWP199, February 1, 2024. Background:The benefits of endovascular thrombectomy (EVT) for posterior cerebral artery (PCA) occlusion remain controversial, but intravenous thrombolysis (IVT) has proven benefit across nearly all ischemic stroke types.
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWP282-AWP282, February 1, 2025. Background:Atrial fibrillation is a common arrhythmia that increases the risk of stroke. Pooled analysis of primary and secondary endpoints showed that apixaban significantly reduced the risk of stroke or systemic embolism by 47% (OR, 0.53(95%CI:
Journal of Cardiovascular Electrophysiology
DECEMBER 23, 2024
ABSTRACT Background Anemia is frequently observed as a comorbidity in atrial fibrillation (AF), especially in elderly patients and in those on anticoagulation. However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07
All About Cardiovascular System and Disorders
FEBRUARY 19, 2024
In an earlier post on Embolic Stroke of Undetermined Source (ESUS) , I had mentioned about ARCADIA trial (AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke) which was testing whether there is role for apixaban compared to aspirin for prevention of recurrent stroke in ESUS.
52 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page A66-A66, February 1, 2024. Introduction:Clinical practice guidelines recommend initiation of anticoagulation within 2 weeks after stroke due to atrial fibrillation (AF). Patients were randomized into one of 4 Arms: Day 3-4 from stroke onset, Day 6, Day 10, or Day 14.
Circulation
NOVEMBER 11, 2023
Background:Device-detected atrial fibrillation (AF) (also known as subclinical AF or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Circulation, Ahead of Print. 0.92; high-quality evidence).
EMS 12-Lead
AUGUST 25, 2024
Examples of cardio embolic stroke etiology include: 1. Atrial Fibrillation 2. Cardiomyopathy with mural thrombus 3. Patent Foramen Ovale 4. Severe calcific Aortic (valve) Stenosis 5. Mechanical prosthetic valve Severe carotid artery stenosis is also implicated in embolic stroke.
59 
Journal of the American Heart Association
JANUARY 19, 2024
The primary efficacy and safety end points were stroke or systemic embolism and major bleeding (International Society on Thrombosis and Hemostasis definition), respectively. The stroke or systemic embolism rate was lower with edoxaban than placebo in both weight groups (≤45 kg: hazard ratio [HR], 0.36 [95% CI, 0.16–0.80];
Open Heart
JULY 1, 2024
Adjusted HRs for stroke or systemic embolism (SE) within 2 years of enrolment were calculated for each NOAC versus VKA. When selecting for ARISTOTLE criteria, apixaban users had significantly lower stroke/SE risk versus VKA (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68
Circulation
JANUARY 20, 2025
Circulation, Volume 151, Issue 3 , Page e29-e29, January 21, 2025.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content